Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Medical Oncology
•
Supportive Care
Based on the FDA indication is fezolinetant (Veozah) in menopause induced hot flashes, is it also used for Aromatase Inhibitor induced hot flashes in the clinical setting?
And where are you offering it in the order of supportive care measures?
Related Questions
Can defibrotide be given safely for VOD in patients with refractory thrombocytopenia to platelet transfusions?
What, if any, resources exist with recommendations regarding the timing and toxicity of radiation in patients who have received or are currently on immunotherapy?
In SIADH due to malignancy, do you prefer to use free water restriction or salt tablets?
How do you mitigate cognitive slowing in elderly patients with mCSPC receiving LHRH agonist therapy?
How do you consider the role of probiotics for mucositis mitigation in patients receiving head and neck radiotherapy?
how do you manage immunotherapy-induced rashes on the face? what is your go-to topical steroid prepartation
How would you treat a patient with newly diagnosed low-risk acute promyelocytic leukemia who has a baseline wide QTc interval, such that arsenic trioxide cannot be used?
What factors would determine which currently approved agent to use as a first line treatment for a stage IV ROS-1 fusion patient with the approval of repotrectinib?
Do you switch therapy to sacituzumab in a patient with metastatic HR+ HER2- breast cancer who has stable systemic disease but new <1cm brain metastasis?
What special considerations do you take when treating cancer patients with severe intellectual disabilities?